Bullish Case: NVAX at $10.46 sits right on Helium's density peak (~$10.50) and market peak ($10.50), with FDA authorization of Novavax-Sanofi Nuvaxovid secured for 2026-27 and healthcare rotation momentum. Call volume runs 84% above puts and bullish risk exceeds bearish by 79%, suggesting upside repricing toward $11.50-$12.50 if rollout demand surprises.

Bearish Case: Price has run 36.6% in sixty days with negative book value (-16.1 P/B), Q2 revenue fell sharply year-over-year, and eligibility restrictions cap the addressable market. Helium's term structure shows spikes at 11/14 (~194%) and Jan/Apr tails (~81-99%), pricing event risk; the market PDF still carries mass at $7.50-$8.50, leaving mean-reversion downside open.

Potential Outcomes:

1. 35% Range $9.50-$11.50 through Nov: FDA authorization priced in, IV decays post 10/16.
2. 25% Rollout/seasonal demand beats → $11.50-$13 by Jan (falsifiable via CDC/pharmacy uptake data).
3. 20% Post-spike mean reversion → $8.50-$9.50 (returns-surface negative bands; low-strike put skew stays bid).
4. 12% M&A/deepening Sanofi integration → >$13 (Sanofi holds commercial rights; deal chatter verifiable in filings).
5. 8% Demand/disappointment shock → <$8 on guidance or supply headlines.

October 03, 2026